Companies: 10,795·Total market cap: $144.5T
Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

CRLNYSEHealthcare● Active
$186.43
+$5.09(+2.81%)
Market Cap$9.0B
P/E Ratio
52W High$228.88
52W Low$140.78
Overview

Charles River Laboratories International, Inc. (CRL) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

crl · stock forecast · 37 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 37 Wall Street analysts in the past 3 months

SellBuy

Buy

37 analysts

consensus

Rating Breakdown

Strong Buy
1
Buy
25
Hold
11
Sell
0
Strong Sell
0
Total: 37 · Buy rate: 70.3%

12-Month Price Target

High

$220

Consensus

$213

+15.3% upside

Low

$192

Median: $217 · Last Close: $184.87

The Charles River Laboratories International, Inc. (CRL) analyst consensus is Buy, based on ratings from 37 Wall Street analysts over the past 3 months. The average 12-month CRL price target is $213.17, representing +15.3% upside from the current price of $184.87.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $213 (15.3%)

Consensus Target

$213.17

15.3% upside

High Target

$220

19.0%

Low Target

$192

3.9%

Current Price

$184.87

as of today

Based on analyst price targets, the CRL stock price prediction for the next 12 months ranges from $192 to $220. The consensus CRL price forecast of $213.17 implies 15.3% upside from the current price of $184.87.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$194.115.00%

1-day model range: $192.87–$195.36. Peak: $195.36 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$190+3.0%
2028$194+4.8%
2029$196+5.9%
2030$197+6.6%
2031+7.0%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

93%0%7%
13Buy
0Neutral
1Sell
RSI (14)76.2Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · CRL · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$181.33BUY
MA 10$177.20BUY
MA 20$167.98BUY
MA 50$171.74BUY
MA 100$176.88BUY
MA 200$177.02BUY
Current $CRL · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$181.78BUY
EMA 10$177.65BUY
EMA 20$173.53BUY
EMA 50$172.19BUY
EMA 100$174.15BUY
EMA 200$174.54BUY
Current $CRL · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
CLSA2026-05-29
Upgrade ↑
HoldOutperform
Barclays2026-05-08
Maintains
OverweightOverweight
Evercore ISI Group2026-05-08
Maintains
OutperformOutperform
Barclays2026-04-14
Maintains
OverweightOverweight
JP Morgan2026-04-13
Maintains
NeutralNeutral
UBS2026-02-25
Maintains
NeutralNeutral
Mizuho2026-02-20
Maintains
NeutralNeutral
TD Cowen2026-02-20
Maintains
BuyBuy
Evercore ISI Group2026-02-19
Maintains
OutperformOutperform
Barclays2026-02-19
Maintains
OverweightOverweight

Wall Street analysts have recently issued updated ratings on Charles River Laboratories International, Inc. (CRL) stock. Of the recent 265 rating actions, 37 were upgrades and 28 were downgrades. 37 analysts currently cover CRL.

Analyst Recommendation Trends

Buy ratings33
Hold ratings202
Sell ratings00

CRL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 3 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$3.8B

↓ 5.9% YoY

Revenue Next Year

$3.9B

↑ 1.8% YoY

EPS This Year

$11.09

EPS Next Year

$12.32

↑ 11.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CRL EPS of $11.09 for the current fiscal year, based on estimates from 10 analysts. The CRL revenue forecast is $3.8B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CRL stock forecast is supported by two independent data sources: analyst consensus ratings from 37 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CRL price target is $213.17 (+15.3% upside), with an analyst consensus of Buy.

The CRL short-term stock prediction for tomorrow is $194.11 (+5.00%). The CRL stock price prediction for 2027 estimates an average of $190. The CRL stock prediction for 2030 projects a range of $183–$211.

Charles River Laboratories International, Inc. trades on NYSE under the ticker CRL. The CRL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 70% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

CRL forecast · 8 questions

According to 37 Wall Street analysts, the average 12-month CRL price target is $213.17, with a high forecast of $220.00 and a low of $192.00. The median price target is shown in the chart above when available. This implies +15.3% potential upside from the current price of $184.87.

CRL price targetWhat is CRL price targetCRL analyst price targetCRL 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.